Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.
Contrary to a widely circulated statement, Covidien’s decision to cut workers and shift production overseas was not motivated by the impending medical device tax, the company says.
The contentious fracas between DePuy and a researcher over a study published in the British Medical Journal may be a preview of the company’s arguments in court.
An independent study of St. Jude Medical’s recalled Riata defibrillator leads finds their survival rate "significantly worse" than rival Medtronic’s Quattro lead.